M. Aoki

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma

S. Iida, T. Ichinohe, Kenshi Suzuki, 2018, International Journal of Hematology.

Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study

S. Iida, N. Tsukada, Kenshi Suzuki, 2017, International Journal of Hematology.

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

T. Doi, T. Nishina, S. Takahashi, 2018, Investigational New Drugs.

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100

K. Ushijima, K. Hasegawa, D. Aoki, 2020, Cancer science.

Long-term Follow-up after Treatment for Cerebrovascular Disease. Semi-long-term Follow-up Results for the Treatment of the Unruptured Cerebral Aneurysms.

T. Yoshimine, A. Kato, E. Kohmura, 2002 .

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

T. Doi, T. Nishina, S. Takahashi, 2018, Investigational New Drugs.